Inventor · disambiguated record
Byron Delabarre
Also filed as: DELABARRE BYRON · DELABARRE BYRON SCOTT
20 granted patents·15 pending applications·184 citations·filing 2011–2024
95Inventor score
Files withSILVER CREEK PHARMACEUTICALS INC7AGIOS PHARMACEUTICALS INC6KINETA INC6OBSIDIAN THERAPEUTICS INC6NIMBUS SATURN INC3
Top patents by PatentIndex Score
35 records- 0197US9512107B2Therapeutically active compositions and their methods of useAGIOS PHARMACEUTICALS INC·Filed 2016·Granted Dec 6, 2016·25 cites·9 claims
- 0296US9656999B2Therapeutically active compounds and their methods of useAGIOS PHARMACEUTICALS INC·Filed 2016·Granted May 23, 2017·16 cites·4 claims
- 0395US9238080B2Bi-specific fusion proteinsNIELSEN ULRIK·Filed 2011·Granted Jan 19, 2016·29 cites·21 claims
- 0494US10988547B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2019·Granted Apr 27, 2021·6 cites·7 claims
- 0594US9732062B2Therapeutically active compounds and their methods of useAGIOS PHARMACEUTICALS INC·Filed 2013·Granted Aug 15, 2017·18 cites·6 claims
- 0694US9718892B2Method of treating myocardial infarction by administering a bi-specific fusion proteinMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Aug 1, 2017·12 cites·10 claims
- 0794US8691771B2Bi-specific fusion proteins for tissue repairNIELSEN ULRIK·Filed 2011·Granted Apr 8, 2014·21 cites·9 claims
- 0893US11666642B2PDE5 compositions and methods for immunotherapyOBSIDIAN THERAPEUTICS INC·Filed 2022·Granted Jun 6, 2023·9 cites·26 claims
- 0993US10858450B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·6 cites·7 claims
- 1093US10407512B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·9 cites·8 claims
- 1192US11241485B2PDE5 compositions and methods for immunotherapyOBSIDIAN THERAPEUTICS INC·Filed 2018·Granted Feb 8, 2022·11 cites·26 claims
- 1291US9982060B2Bi-specific fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·9 cites·15 claims
- 1390US11814443B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·1 cites·20 claims
- 1490US10294215B2Therapeutically active compounds and their methods of useAGIOS PHARMACEUTICALS INC·Filed 2017·Granted May 21, 2019·6 cites·32 claims
- 1589US2024101713A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1688US11673970B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Jun 13, 2023·1 cites·7 claims
- 1787US12104178B2DHFR tunable protein regulationOBSIDIAN THERAPEUTICS INC·Filed 2021·Granted Oct 1, 2024·1 cites·7 claims
- 1887US2023322951A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1986US11926625B2HPK1 antagonists and uses thereofNIMBUS SATURN INC·Filed 2022·Granted Mar 12, 2024·1 cites·17 claims
- 2086US11505538B1Therapeutically active compounds and their methods of useAGIOS PHARMACEUTICALS INC·Filed 2020·Granted Nov 22, 2022·1 cites·8 claims
- 2184US11629340B2DHFR tunable protein regulationOBSIDIAN THERAPEUTICS INC·Filed 2019·Granted Apr 18, 2023·2 cites·29 claims
- 2282US2023250078A1Therapeutically active compounds and their methods of useSERVIER PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 2377US2024401004A1Dhfr tunable protein regulationOBSIDIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2472US2024199603A1Hpk1 antagonists and uses thereofNIMBUS SATURN INC·Filed 2024·Application pending·0 cites
- 2569US2020079755A1Therapeutically active compounds and their methods of useAGIOS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2662US2025353851A1Purines and methods of their useKINETA INC·Filed 2022·Application pending·0 cites
- 2760US2025288589A1Pyridopyrimidines and methods of their useKINETA INC·Filed 2022·Application pending·0 cites
- 2860US2025145642A1Bicyclic heteroarenes and methods of their useKINETA INC·Filed 2022·Application pending·0 cites
- 2955US12252488B2HPK1 antagonists and uses thereofNIMBUS SATURN INC·Filed 2022·Granted Mar 18, 2025·0 cites·22 claims
- 3054US2024208964A1Pyridopyrimidines and methods of their usePYRIDOPYRIMIDINES AND METHODS OF THEIR USE·Filed 2021·Application pending·0 cites
- 3154US2024150358A1Purines and methods of their useKINETA INC·Filed 2021·Application pending·0 cites
- 3253US2023271965A1Bicyclic heteroarenes and methods of their useKINETA INC·Filed 2021·Application pending·0 cites
- 3351US2024166624A1Pparg inverse agonists and uses thereofFLARE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3445US2022403001A1Pde5 derived regulatory constructs and methods of use in immunotherapyOBSIDIAN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3539US2023339890A1Amino alcohol compounds and uses thereofKINETA INC·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →